What this domain asks
Risk that product, substance, device, market, registration, license, activity, authority, commitment, correspondence, and approval information is fragmented or too unreliable to support global regulatory decisions and market continuity.
The domain should retain its own evidence, decision owner, materiality criteria, exception path, and consequence even when it shares organization identity, workflow, or technology with adjacent domains. Aggregation can support oversight; it should not erase the evidence behind different risks or operating outcomes.
Buyer questions
- What is the product and registration data model, and can it represent the organization's drugs, biologics, devices, IVDs, packs, presentations, and markets without forcing false equivalence?
- How are applications, registrations, variations, commitments, correspondence, approvals, renewals, and expirations related?
- Which data originates in RIM, ERP, PLM, labeling, safety, master-data, or authority systems, and who stewards each source?
- Can a product or manufacturing change identify every affected market, dossier, label, commitment, and supply decision?
- How are authority-specific classifications, controlled vocabularies, and implementation dates maintained and evidenced?
- Can the organization reconstruct what was submitted, approved, effective, and marketable at a historical point in time?
Mapped workflows
Change Control
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for change control within this domain.
Regulatory Product And Registration Data
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for regulatory product and registration data within this domain.
Regulatory Activity And Commitment Tracking
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for regulatory activity and commitment tracking within this domain.
Submission Planning And Dossier Management
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for submission planning and dossier management within this domain.
Labeling And Structured Product Data
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for labeling and structured product data within this domain.
Health-Authority Correspondence
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for health-authority correspondence within this domain.
Analytics And Management Review
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for analytics and management review within this domain.
Authority context
FDA 21 CFR Part 11
Part 11 defines criteria under which FDA considers electronic records, electronic signatures, and handwritten signatures executed to electronic records trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.
EU MDR
The MDR establishes rules for placing medical devices on the EU market and covers economic operators, conformity assessment, quality systems, clinical evidence, technical documentation, UDI, registration, vigilance, post-market surveillance, and market surveillance.
EU IVDR
The IVDR establishes rules for in vitro diagnostic devices, including classification, conformity assessment, quality systems, performance evidence, technical documentation, UDI, registration, vigilance, post-market surveillance, and performance studies.
eCTD v4.0
eCTD v4.0 defines a harmonised structure and exchange model for regulatory submissions, with regional controlled vocabularies, module-one requirements, validation criteria, transmission specifications, and implementation timelines maintained by authorities.
ISO IDMP
The ISO IDMP family standardizes the identification and description of substances, dose forms and routes, units of measurement, regulated pharmaceutical products, and regulated medicinal products. EMA is implementing these concepts through substance, product, organization, and referential master-data services.
Relevant operating models
- Integrated Quality And Regulatory Platform
- Enterprise Regulatory Information Management Suite
- Regulatory Submissions And Publishing Platform
- Medical-Device Regulatory Information Management
- Regulatory Content And Document Management
Evidence boundary
RegQuality Review is not a regulator, certification body, law firm, or validation authority. Its records support research and decision review; they do not establish compliance for an organization, system, release, configuration, or intended use. A provider's documented capability can identify a research candidate but cannot establish buyer-specific adequacy for this domain.